Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2024 07:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

-Webcast investor event on September 14, 2024 at 9:00 a.m. ET -ESMO poster presentation to provide updated ACR-368 clinical data in endometrial cancer -Webcast to provide updates on its lead assets...
August 13, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon...
May 29, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
May 14, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
April 24, 2024 16:01 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed overall...
April 16, 2024 20:01 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
April 10, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in...
April 09, 2024 07:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Announces $130 Million Private Placement Financing

WATERTOWN, Mass, April 09, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
March 28, 2024 08:00 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

WATERTOWN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision...
March 05, 2024 16:30 ET | Source: Acrivon Therapeutics, Inc

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

ACR-2316, a novel, selective dual WEE1 and PKMYT1 inhibitor development candidate, designed using AP3 to achieve superior single agent activity, demonstrates potent preclinical activity across studies...